A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

Background Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting. Objective To evaluate long-term safety ...

Background Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further ...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence ...

A woman from Jersey said her life "changed forever" after she was diagnosed with skin cancer. Rhona Hewit, 64, discovered a ...

Relapsing Multiple Sclerosis: Navigating Treatment Conundrums This activity is supported by an educational grant from Novartis Pharmaceuticals, Inc.

Novel immunomodulatory agents have considerably improved the treatment of multiple sclerosis in recent years, but inhibiting disease progression remains a central challenge. This article describes ...

This review will examine recent advancements in CAR Tcell therapy for autoimmune disorders, highlighting how CAR T cells can be engineered to precisely target and eliminate autoreactive immune cells ...

In this review, we provide an overview of the BM microenvironment perturbation in MM patients and how it can determine the possible resistance to immunotherapy, including monoclonal antibodies (mAbs), ...